Objective: This study aimed to evaluate the clinical impact of liraglutide 3.0 mg in improving female patients’ weight and assess its impact on improvements in their OG-RC.
Methods: This was a retrospective study of participants who took liraglutide 3.0 mg for ≥ 3 months’ duration in the OB/GYN clinic at Dr. Sulaiman Al-Habib (Habib Medical Group) in Riyadh, Saudi Arabia. The primary endpoint was to assess the mean average weight loss among female patients using liraglutide 3.0 mg. The secondary endpoints included clinical improvement in OG-RC.
Results: At the end of the study, 31 patients met the inclusion criteria. The average weight loss was 7.9 kg or 8.7% of the initial body weight. The BMI dropped by -3.1 kg/m2 Most patients had lost more than 5% of their initial body weight, while around half of the patients had lost >10% of their initial body weight. The OG-RC significantly improved during the clinical intervention period, 73.6% of patients complaining of PCOS symptoms had improved, and two-thirds of the patients had an overall improvement in getting pregnant, while most patients had also tolerated the liraglutide 3.0 mg usage.
Conclusion: Liraglutide 3.0mg daily has shown significant clinical effectiveness towards weight loss among women visiting OB/GYN clinics with a clinical improvement in their OG-RC.
Key words: Women’s health, PCOS, obesity, liraglutide, IVF, weight loss, obstetrics and gynecology-related
complications.
|
